MUVON Therapeutics is proud to announce the acceptance as a Wyss Zurich Project starting April 2021.
The Wyss Zurich is a joint accelerator of the University of Zurich and ETH Zurich (Swiss Federal Institute of Technology Zurich), which was made possible by a generous donation from the Swiss entrepreneur and philanthropist Dr. h.c. mult. Hansjörg Wyss. It was established to foster translational research focused on developing treatment protocols and clinical therapies, as well as novel technologies and intelligent systems, in the emerging fields of Regenerative Medicine, Robotics, and hybrid technologies thereof. Wyss Zurich unites world-leading experts from both institutions in multidisciplinary teams, pooling their knowledge and expertise. For more information, please visit www.wysszurich.ch
With funding and further support from Wyss Zurich (such as access to GMP facilities and experienced platform teams) the MUVON project will focus on the clinical and commercial development of MUVON’s MPC Therapy for the treatment of stress urinary incontinence and evaluate the therapy’s efficacy during a phase II clinical trial. The project builds on the previous successful collaboration between the MUVON Team and Wyss Zurich in the scope of the associate project MUS.I.C. which covered the establishment of a GMP validated production process and the manufacturing for MUVON’s phase I clinical trial.
Comments